SNX-5422

prodrug of PF-04928473; orally bioavailable heat shock protein 90 inhibitor

Also Known As:

PF 04929113; PF-04929113; PF-4929113; PF04929113; SNX-5422 mesylate; glycine trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl)phenyl)amino)cyclohexyl ester

Networked: 9 relevant articles (0 outcomes, 5 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Giaccone, Giuseppe: 2 articles (12/2021 - 11/2011)
2.	Gutierrez, Martin: 2 articles (12/2021 - 11/2011)
3.	Hinson, James M: 2 articles (12/2021 - 08/2013)
4.	Fazli, Ladan: 2 articles (07/2014 - 04/2011)
5.	Gleave, Martin E: 2 articles (07/2014 - 04/2011)
6.	Thomas, Christian: 2 articles (07/2014 - 04/2011)
7.	Yin, Min-Jean: 2 articles (07/2014 - 04/2011)
8.	Zoubeidi, Amina: 2 articles (07/2014 - 04/2011)
9.	Brega, Nicoletta: 2 articles (08/2013 - 11/2011)
10.	Houk, Brett E: 2 articles (08/2013 - 11/2011)

Related Diseases

1.	Neoplasms (Cancer) 12/17/2021 - "We demonstrate that an orally bioavailable Hsp90 inhibitor, SNX-5422, currently in clinical trials as an anti-cancer therapeutic, inhibits SARS-CoV-2 replication in vitro at a high selectivity index. " 12/01/2021 - "Cancers for which disease control on single-agent SNX-5422 maintenance was observed were enriched for oncogene-driven NSCLCs." 04/15/2011 - "Finally, PF-04929113 inhibited tumor growth and prolonged survival compared with controls. " 12/01/2021 - "Patients who remained on single-agent SNX-5422 maintenance therapy ≥2 months (n = 9) had cancers enriched for oncogenic drivers (n = 3 KRAS mutation, n = 1 EGFR exon 20 mutation, n = 1 HER2 mutation, and n = 1 RET fusion). " 11/01/2011 - "To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas. "
2.	Hematologic Neoplasms (Hematological Malignancy) 08/01/2013 - "Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies." 01/01/2021 - "We report here preclinical data suggesting that the Hsp90 inhibitor SNX-5422, which has been pursued in clinical trials in both solid tumor and hematological malignancies, is a potential therapy for ibrutinib resistant CLL."
3.	Lymphoma (Lymphomas) 11/01/2011 - "To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas. " 11/01/2011 - "A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas."
4.	Toxic Optic Neuropathy 11/01/2011 - "Although no clinically significant drug-related ocular toxicity was seen in this study, the development of PF-04929113 has been discontinued because of ocular toxicity seen in animal models and in a separate phase I study."
5.	Lung Neoplasms (Lung Cancer) 12/01/2021 - "Therefore, we conducted a phase 1, open-label, multicenter study to evaluate SNX-5422, carboplatin and paclitaxel followed by SNX-5422 maintenance in patients with advanced lung cancers. " 12/01/2021 - "Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers."

Related Drugs and Biologics

1.	Heat-Shock Proteins (Heat-Shock Protein)
2.	ibrutinib
3.	6- chloro- 9- (4- methoxy- 3,5- dimethylpyridin- 2- ylmethyl)- 9H- purin- 2- ylamine
4.	tanespimycin (17AAG)
5.	Prostate-Specific Antigen (Semenogelase)
6.	Paclitaxel (Taxol)
7.	Carboplatin (JM8)
8.	apatorsen

Related Therapies and Procedures

1.	Therapeutics